Skip to Main Content

Paper Details

Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease.
Cell Host Microbe
72
2021
-, Crohn's disease, IBD, IL12/23, Patients, anti-TNF, inflammatory bowel disease, integrin, patients, ulcerative colitis
Author NameAffiliation
Larson HogstromBroad Institute of MIT and Harvard
Clary B ClishBroad Institute of MIT and Harvard
Clary B ClishBroad Institute of MIT and Harvard
Ramnik J XavierBroad Institute of MIT and Harvard, USA Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, USA Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School
Ramnik J XavierBroad Institute of MIT and Harvard, USA Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, USA Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School
Ashwin N AnanthakrishnanMassachusetts General Hospital
  • 1 - 6

Datasets